3b Blackbio Dx Ltd · NSE:3BBLACKBIO
3b Blackbio Dx — Kilpest India — Q2 FY2022 Earnings Presentation
30 slides from 3b Blackbio Dx's earnings presentation, Nov 11, 2021
Slide 1: Cover letter to BSE
REGD. OFFICE & FACTORY : 7-C, INDUSTRIAL AREA, GOVINDPURA, BHOPAL - 462 023 INDIA KILPEST INDIA LIMITED SGC seo eoow sooo Tel =: 91-755 2586536, 2586537 E-mail : kilpest@bsni.in Visit us at : www.kilpest.com kilpestbpl|@yahoo.co.in CIN : L24214MP1972PLC001131 November 11, 2021 The Relationship Manag
Slide 2: Investor Presentation November 2021
Farmer’s Trusted Agro-Input Partner for 49 Years Reliable and Affordable Healthcare Diagnostic Solutions INVESTOR PRESENTATION NOVEMBER’ 2021
Slide 3: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Kilpest India Limited and 3B BlackBio Biotech India Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation t
Slide 4: Financial Performance and Key Highlights
FINANCIAL PERFORMANCE AND KEY HIGHLIGHTS
Slide 5: Performance Highlights – Q2 2021-22
Performance Highlights – Q2 2021-22 KILPEST (Consolidated) Q2 FY22 Q2 FY21 H1FY22 11227.60 7977.42 Net sales 1522.01 11227.60 4788.80 2022 2021 Profit before tax 769.79 7977.42 2727.80 Profit after tax 587.76 5973.25 2081.33 Paid up Equity share capital 750.81 750.81 750.81 1522.01 769.79 Reserves 1
Slide 6: We Are Proud To Be A Part Of
WE ARE PROUD TO BE A PART OF Forbes Asia BF UNDERA BILLION 2021 00 (Nha Cotter
Slide 7: Key Highlights - Agrochemicals
Key Highlights - Agrochemicals Impact of COVID-19 ❑ There was a potential loss in the production/sales during the H1 of FY22. ❑ The sales for the H1 remain static for agrochemicals. ❑ Company continues to focus on Public Health/Warehousing sector and Exports. As due to COVID-19, Private agriculture
Slide 8: Kilpest Existing Products
Kilpest Existing Products Chemicals Biologicals No. of Products No. of Products • Insecticides 70 • Bio pesticide 07 • Antibacterials 01 • Bio fungicide 01 • Fungicides 15 • Bio fertilizers 05 • Herbicides 11 • Bio nematicides 01 • Public Health 11 • Public Health 02 • Microfertilizers 02 • Health &
Slide 9: From the house of Kilpest India Ltd.
Since 1972 From the house of Kilpest India Limited, KILPEST INDIA LTD. India’s most trusted agro-chemical brand proudly brings First licensed Molecular Diagnostics (IVD) manufacturing facility in India under Medical Device Rule 2017 ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GEN
Slide 10: Introduction – 3B BlackBio Biotech India Limited
Introduction – 3B BlackBio Biotech India Limited “3B BlackBio Biotech India Limited”, a subsidiary of Kilpest India Limited, embarked on its mission in 2011 with a vision to provide reliable, accurate and affordable healthcare solutions to all. Ever since its inception, 3B BlackBio is engaged in Des
Slide 11: TRUPCR® from 3B BlackBio Biotech (I) Ltd.
TRUPCR® from 3B BlackBio Biotech (I) Ltd. Our Vision: Our Mission: To offer reliable, affordable and To design and develop molecular effective healthcare solutions to all diagnostics products of superior by recognizing the great potential of quality and value that continuously biotechnology to effec
Slide 12: Timeline & Milestones
Timeline & Milestones COVID-19 YEAR GONE GLOBAL TRUPCR® Launching SARS-CoV- Launch of Oncopanel 2 Launch s MANCHESTER of Solid qPCR Extending Tumor AML Menu with SITE Virology & Kit ALL Public EGFR Health (USFDA- Adding MPN KRAS EUA) Virology Entering & HBV, HCV Launch of Oncology Expanding Geno, HI
Slide 13: Growth Canvas
Growth Canvas ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 14: Financial Highlights – Q2 FY 2021-22
Financial Highlights – Q2 FY 2021-22 10733.40 7844.29 1148.60 756.43 Revenue EBITDA 7837.29 5860.08 Q1FY22 Q2FY21 588.67 743.43 PAT PBT Rs. In Lakhs. * The figures of Year 2020-21 cannot be compared due to COVID-19 which was a one-time happening ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEA
Slide 15: Business Outlook – Post COVID
Business Outlook – Post COVID Due to COVID-19, nationally and internationally, number of Molecular Diagnostics Labs and manufacturers have increased manifolds, but with COVID-19 infections potentially decreasing after June 2021, a lot of labs might shut down due to non-viability, still there would b
Slide 16: Manchester Project
Manchester Project With the acquisition of 70% stake in HS Biolabs Ltd., it will become a subsidiary of 3B BlackBio. The objectives of this acquisition are: ➢ offering “Made in UK” products which will give much higher product acceptability to the company’s products globally; ➢ accelerate the manufac
Slide 17: Utilization of Funds, Scheme of Amalgamation, Proposed NSE Listing
Utilization of Funds We are looking for options to acquire a company in similar business area to get inorganic growth in FY22 and onwards. We will only go for the acquisition if it makes financial sense and meets our internal IRR criteria. We would also be looking at share buyback in FY22/23 if we a
Slide 18: Rapid Antigen Vertical, Expansion and NGS Vertical
Rapid Antigen Business Vertical Company’s continuous focus on the Research and development (R&D) activities is a valuable tool for growing and improving business. Company strongly believes that businesses that have an R&D strategy have a greater chance of success than businesses that do not. Company
Slide 19: Exports
Exports This year we want to focus on exports. Our products have been well-accepted in more than 25 countries. With the export restriction now removed, we have fast paced our marketing strategy for the international customers. We are in discussion with many key customers internationally and hope tha
Slide 20: R&D and People
R&D R&D People •Highly educated team of scientist from varied backgrounds •Dedicated teams for respective segments •Separate onco team headed by researchers (Ph.Ds.) from oncology background •Separate team for infectious parameters headed by researchers (Ph.Ds.) from infectious diseases background L
Slide 21: Product QC - Our Strength
Product QC - Our Strength All TRUPCR® products are passed through stringent QC protocols to ensure optimal performance at customer site • QC of raw material • QC of every final lot • Cherrypicked QC of final batch Besides above routine QC practices, Kits are QC checked on respective* real-time cycle
Slide 22: Our Certificates
Our Certificates US FDA EUA COVID-19 Award of RT-PCR Kit Excellence For Leading CDSCO Licensed IVD Company Diagnostic Kits of the year 2020-21 ISO 13485:2016 Certified Company ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 23: Technology Focus
Technology Focus High Volume Cytogenetics Real-Time PCR 3B’s Focus Low Growth High Growth Other Molecular Techniques Mass Spec Hybridization Sanger Sequencing Next Generation Sequencing Low Volume Microarray ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 24: Product Segments
Product Segments ONCOLOGY ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 25: All Inclusive TRUPCR® Products
All Inclusive TRUPCR® Products TRUPCR® range of products offers end-to-end standardized solutions from samples to optimized end-results Nucleic Acid Detection Sample Nucleic Acid Nucleic Acid Extraction & and Management Preparation Amplification Purification Analysis Sample stabilization TRUPCR ® Nu
Slide 26: Global Recognition
Global Recognition ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS
Slide 27: Growth Drivers
Growth Drivers • Improvement in Indian healthcare industry with high demand in medical tourism • Increasing number of molecular tests being introduced by labs • Evolution of disease profiles. New viruses and cancers are been diagnosed External Growth Drivers • Increase in evidence-based treatments /
Slide 28: National MSME Award 2018
National MSME Award- 2018 by Hon'ble President of India, Shri Ram Nath Kovind. Hon'ble President of India, Shri Ram Nath Kovind on Friday on the occasion of 20th National Technology Day presented the national award for successful commercialization of indigenous technology at Vigyan Bhavan, New Delhi
Slide 29: Outstanding Achievement Award for Excellence in R&D by FMPCCI
Outstanding Achievement Award for Excellence in R&D by FMPCCI, Bhopal. 3B BLACKBIO BIOTECH (I) LTD. Bhopal is awarded with the ‘Outstanding Achievement Award in recognition of excellence in R&D through technology in MSME enterprise category’, during the 4th Outstanding Achievement Award 2016, held o
Slide 30: Jai Hind
JAI HIND ONCOLOGY INFECTIOUS DISEASES WOMEN’S HEALTH PUBLIC HEALTH HUMAN GENETICS